Clinical Trials
24 trialsNCT06833008 2026-06-01
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT07617493 2026-06-01
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07615660 2026-05-29
CVL006-T1003
Convalife (Shanghai) Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05052268 2026-05-28
XTX202 in Patients With Advanced Solid Tumors
Xilio Development, Inc.
Phase 1/2 Completed
NCT05599048 2026-05-27
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
University of California, San Francisco
Phase 1/2 Recruiting
NCT05170958 2026-05-15
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT07587879 2026-05-14
mRNA-LNP
IntraAb, Inc.
Phase 1/2 Not yet recruiting
NCT04322006 2026-05-13
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
Phase 1/2 Completed
NCT05438329 2026-05-12
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Active not recruiting
NCT06685068 2026-05-08
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
NCT04896697 2026-05-05
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Xilio Development, Inc.
Phase 1/2 Active not recruiting
NCT05038150 2026-05-05
Study of SGN1 in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT05103345 2026-05-05
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT05580770 2026-05-01
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1/2 Terminated
NCT07298772 2026-05-01
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT07300943 2026-05-01
Study in Advanced Solid Tumor Patients
Callio Therapeutics
Phase 1/2 Recruiting
NCT05451602 2026-04-28
HEC169096 in Participants With Advanced Solid Tumors
Sunshine Lake Pharma Co., Ltd.
Phase 1/2 Recruiting
NCT06470763 2026-04-14
EXPAND-1
Anaveon AG
Phase 1/2 Active not recruiting
NCT06635785 2026-04-09
BiPAVE-001
OncoC4, Inc.
Phase 1/2 Recruiting
NCT06911827 2026-04-07
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT07512583 2026-04-06
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07508761 2026-04-02
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Nanjing Immunophage Biotech Co., Ltd
Phase 1/2 Not yet recruiting
NCT06953323 2026-03-27
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06253130 2026-03-23
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Eikon Therapeutics
Phase 1/2 Recruiting